TY - JOUR
T1 - Asthma
T2 - New integrative treatment strategies for the next decades
AU - Arteaga-Badillo, Diego A.
AU - Portillo-Reyes, Jacqueline
AU - Vargas-Mendoza, Nancy
AU - Morales-González, José A.
AU - Izquierdo-Vega, Jeannett A.
AU - Sánchez-Gutiérrez, Manuel
AU - Álvarez-González, Isela
AU - Morales-González, Ángel
AU - Madrigal-Bujaidar, Eduardo
AU - Madrigal-Santillán, Eduardo
N1 - Publisher Copyright:
© MDPI AG. All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - Asthma is a chronic disease whose main anatomical–functional alterations are grouped into obstruction, nonspecific bronchial hyperreactivity, inflammation and airway remodeling. Currently, the Global Initiative of Asthma 2020 (GINA 2020) suggests classifying it into intermittent cases, slightly persistent, moderately persistent and severely persistent, thus determining the correct guidelines for its therapy. In general, the drugs used for its management are divided into two groups, those with a potential bronchodilator and the controlling agents of inflammation. However, asthmatic treatments continue to evolve, and notable advances have been made possible in biological therapy with monoclonal antibodies and in the relationship between this disease and oxidative stress. This opens a new path to dietary and herbal strategies and the use of antioxidants as a possible therapy that supports conventional pharmacological treatments and reduces their doses and/or adverse effects. This review compiles information from different published research on risk factors, pathophysiology, classification, diagnosis and the main treatments; likewise, it synthesizes the current evidence of herbal medicine for its control. Studies on integrative medicine (IM) therapies for asthmatic control are critically reviewed. An integrative approach to the prevention and management of asthma warrants consideration in clinical practice. The intention is to encourage health professionals and scientists to expand the horizons of basic and clinical research (preclinical, clinical and integrative medicine) on asthma control.
AB - Asthma is a chronic disease whose main anatomical–functional alterations are grouped into obstruction, nonspecific bronchial hyperreactivity, inflammation and airway remodeling. Currently, the Global Initiative of Asthma 2020 (GINA 2020) suggests classifying it into intermittent cases, slightly persistent, moderately persistent and severely persistent, thus determining the correct guidelines for its therapy. In general, the drugs used for its management are divided into two groups, those with a potential bronchodilator and the controlling agents of inflammation. However, asthmatic treatments continue to evolve, and notable advances have been made possible in biological therapy with monoclonal antibodies and in the relationship between this disease and oxidative stress. This opens a new path to dietary and herbal strategies and the use of antioxidants as a possible therapy that supports conventional pharmacological treatments and reduces their doses and/or adverse effects. This review compiles information from different published research on risk factors, pathophysiology, classification, diagnosis and the main treatments; likewise, it synthesizes the current evidence of herbal medicine for its control. Studies on integrative medicine (IM) therapies for asthmatic control are critically reviewed. An integrative approach to the prevention and management of asthma warrants consideration in clinical practice. The intention is to encourage health professionals and scientists to expand the horizons of basic and clinical research (preclinical, clinical and integrative medicine) on asthma control.
KW - Antioxidants
KW - Asthma
KW - Diagnosis
KW - Oxidative stress
KW - Treatment strategies
UR - http://www.scopus.com/inward/record.url?scp=85090181203&partnerID=8YFLogxK
U2 - 10.3390/medicina56090438
DO - 10.3390/medicina56090438
M3 - Artículo de revisión
C2 - 32872366
AN - SCOPUS:85090181203
SN - 1010-660X
VL - 56
SP - 1
EP - 19
JO - Medicina (Lithuania)
JF - Medicina (Lithuania)
IS - 9
M1 - 438
ER -